Cargando…
Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles
BACKGROUND: Design and analysis of clinical trials for rare and ultra-rare disease pose unique challenges to the practitioners. Meeting conventional power requirements is infeasible for diseases where sample sizes are inherently very small. Moreover, rare disease populations are generally heterogene...
Autores principales: | Kidwell, Kelley M., Roychoudhury, Satrajit, Wendelberger, Barbara, Scott, John, Moroz, Tara, Yin, Shaoming, Majumder, Madhurima, Zhong, John, Huml, Raymond A., Miller, Veronica |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077995/ https://www.ncbi.nlm.nih.gov/pubmed/35526036 http://dx.doi.org/10.1186/s13023-022-02342-5 |
Ejemplares similares
-
Accelerating Rare Disease Drug Development: Lessons Learned from Muscular Dystrophy Patient Advocacy Groups
por: Huml, Raymond A., et al.
Publicado: (2020) -
A Tutorial on Modern Bayesian Methods in Clinical Trials
por: Muehlemann, Natalia, et al.
Publicado: (2023) -
Public policy action and CCC implementation: benefits and hurdles
por: Steger, Carter, et al.
Publicado: (2010) -
Hurdles to Cardioprotection in the Critically Ill
por: See Hoe, Louise E, et al.
Publicado: (2019) -
Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturity
por: Heeg, Bart, et al.
Publicado: (2023)